We further tested the association between survivin expression and ibrutinib resistance in a second independent MCL patient cohort (n = 21) that included 15 ibrutinib-responsive and 6 NR tumors and confirmed higher survivin expression in nonresponders (Fig. 5d). This evidence concerns the gene BIRC5 and mantle cell lymphoma.